IL156689A0 - Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof - Google Patents

Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Info

Publication number
IL156689A0
IL156689A0 IL15668901A IL15668901A IL156689A0 IL 156689 A0 IL156689 A0 IL 156689A0 IL 15668901 A IL15668901 A IL 15668901A IL 15668901 A IL15668901 A IL 15668901A IL 156689 A0 IL156689 A0 IL 156689A0
Authority
IL
Israel
Prior art keywords
epitopes
antibodies
isolated molecules
containing sulfated
sulfated moieties
Prior art date
Application number
IL15668901A
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of IL156689A0 publication Critical patent/IL156689A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15668901A 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof IL156689A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25894800P 2000-12-29 2000-12-29
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049442 WO2002053700A2 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Publications (1)

Publication Number Publication Date
IL156689A0 true IL156689A0 (en) 2004-01-04

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15668901A IL156689A0 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Country Status (13)

Country Link
EP (1) EP1406930A4 (en)
JP (1) JP2005503756A (en)
KR (1) KR20030091953A (en)
CN (1) CN100347194C (en)
BR (1) BR0116764A (en)
CA (1) CA2433225A1 (en)
CZ (1) CZ20031982A3 (en)
HU (1) HUP0700079A2 (en)
IL (1) IL156689A0 (en)
MX (1) MXPA03005945A (en)
PL (1) PL366223A1 (en)
RU (1) RU2003123101A (en)
WO (1) WO2002053700A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
EP1551452A4 (en) * 2002-07-01 2006-08-30 Savient Pharmaceuticals Inc Compositions and methods for therapeutic treatment
RU2006102571A (en) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) SPECIFIC HUMAN ANTIBODIES
RU2006102570A (en) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) ANTIBODIES AND THEIR APPLICATION
ITMI20031714A1 (en) * 2003-09-05 2005-03-06 Gentium Spa FORMATIONS FOR ANTITUMORAL ACTION.
UY28886A1 (en) 2004-05-10 2005-12-30 Boehringer Ingelheim Int ANTIBODIES CONSISTING IN POLYPEPTIDES AND DERIVATIVES UNDERSTANDING THREE SEQUENCES CONCERNING THE FOLLOWING NUMBERS OF SEQ. ID: 1-3 AND 4-6; 7-9 AND 10-12 AND 13-15 OR 16-18
WO2005110456A2 (en) 2004-05-11 2005-11-24 Abgenomics Corporation T-cell death-inducing epitopes
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
RU2627177C2 (en) 2012-06-22 2017-08-03 Джентиум С.Р.Л. Method for defibrotide biological activity determination, based on euglobulin application
WO2016013828A1 (en) * 2014-07-21 2016-01-28 연세대학교 산학협력단 Extracellular domain 1 mutant of sulfated duffy chemokine receptor, and use thereof
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
WO2019027034A1 (en) * 2017-08-04 2019-02-07 公立大学法人福島県立医科大学 Novel polypeptide and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011778A1 (en) * 1991-12-12 1993-06-24 The Scripps Research Institute Bifunctional antithrombotic molecules and antithrombotic polypeptides
CZ401497A3 (en) * 1995-06-14 1998-07-15 The General Hospital Corporation P-selectin ligands and related molecules and processes
DK0850243T3 (en) * 1995-08-03 2004-02-02 Univ Oklahoma O-Glycan Inhibitors of Selectin-Mediated Inflammation
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US6593459B1 (en) * 1998-06-16 2003-07-15 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof

Also Published As

Publication number Publication date
MXPA03005945A (en) 2004-10-15
CN1649900A (en) 2005-08-03
JP2005503756A (en) 2005-02-10
WO2002053700A2 (en) 2002-07-11
EP1406930A4 (en) 2007-01-10
EP1406930A2 (en) 2004-04-14
WO2002053700A3 (en) 2004-02-12
CA2433225A1 (en) 2002-07-11
BR0116764A (en) 2007-01-09
HUP0700079A2 (en) 2007-05-02
PL366223A1 (en) 2005-01-24
RU2003123101A (en) 2005-03-10
CN100347194C (en) 2007-11-07
KR20030091953A (en) 2003-12-03
CZ20031982A3 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
MXPA03001590A (en) ANTIBODIES TO HUMAN IL-1bgr;.
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
ZA200400521B (en) Antibodies to OPGL.
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
AU3662101A (en) Cd40-binding apc-activating molecules
GB0029360D0 (en) Humanised antibodies and uses thereof
IL156689A0 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
GB0002093D0 (en) Antiperspirants
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
AU2002365894A8 (en) Antibodies to magmas and uses thereof
GB0115428D0 (en) Antibodies, peptides, analogs and uses thereof
MXPA03005511A (en) Antiperspirant cloths.
AU2002221132A1 (en) Novel antibody
GB0022670D0 (en) Molecules
GB0002625D0 (en) Dendroaspin molecules
GB0031284D0 (en) High affinity antibodies
GB0020568D0 (en) Novel antibody
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
AU2001236588A1 (en) Antibodies to the staphylococcal multidrug resistance (smr) protein
GB0003527D0 (en) Antibodies
GB0019640D0 (en) Improvements to bottle
GB0005728D0 (en) Conserved antigens
GB0009538D0 (en) Antibody binding
GB0003359D0 (en) Monoclonal antibodies